OKUR
Income statement / Annual
Last year (2024), OnKure Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, OnKure Therapeutics, Inc.'s net income was -$52.67 M.
See OnKure Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$43.80 M
|
$32.12 M
|
$25.86 M
|
| General & Administrative Expenses |
$10.59 M
|
$4.82 M
|
$3.90 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.59 M
|
$4.82 M
|
$3.90 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$54.39 M
|
$36.93 M
|
$29.77 M
|
| Cost And Expenses |
$54.39 M
|
$36.93 M
|
$29.77 M
|
| Interest Income |
$2.01 M
|
$1.62 M
|
$254,000.00
|
| Interest Expense |
$300,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$662,000.00
|
$560,000.00
|
$387,000.00
|
| EBITDA |
-$51.71 M |
-$34.75 M |
-$29.38 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.71 M
|
$1.62 M
|
$254,000.00
|
| Income Before Tax |
-$52.67 M
|
-$35.31 M
|
-$29.51 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$52.67 M
|
-$35.31 M
|
-$29.51 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-3.95 |
-2.65 |
-2.21 |
| EPS Diluted |
-3.95 |
-2.65 |
-2.21 |
| Weighted Average Shares Out |
$13.34 M
|
$13.34 M
|
$13.34 M
|
| Weighted Average Shares Out Diluted |
$13.34 M
|
$13.34 M
|
$13.34 M
|
| Link |
|
|
|
